J. Edward Moreno

Reporter @Sherwood_News. Say hi: [email protected], jedwardmoreno.04 on Signal

[J. Edward Moreno @edwrdmoreno]

Enhanced Group $ENHA is spending $31 million to put on a controversial, uninsurable event challenging legacy sports associations. It’s really a high stakes product demo for a longevity business. https://t.co/0A5daoeRm6

[David Crowther @ChiefChartmaker]

Robinhood traders love to buy the dip.

Never before seen data from our new newsletter; EntryPoint, shows HOOD traders buying the dip and selling the rip on April 30th.

(Hard to buy dips when they haven't really existed these last 2 weeks).

[Luke Kawa @LJKawa]

Thrilled to be debuting the EntryPoint newsletter with @ChiefChartmaker, who kicks off our launch party here:
https://t.co/0A92BEFRSD

We’ll be featuring insights on the trends the define the price action, and data on Robinhood trader flows you won’t find anywhere else.

[Joshua Topolsky @joshuatopolsky]

Really excited to share this. The most interesting stories in the market aren't the ones you can always see. EntryPoint shows you where to look.

Sign up here: https://t.co/3UmH7XaAb5

[J. Edward Moreno @edwrdmoreno]

This week I spoke to John Love, the head of $AMZN Pharmacy, about its GLP-1 offerings and its plans to expand its footprint. https://t.co/f3OEi3iFTc

[Jake Lahut @JakeLahut]

Tulsi Gabbard has been told by the White House that she has until the midterms to pack up and leave, according to sources I've spoken to in recent weeks. https://t.co/s5sptxcT9m

[J. Edward Moreno @edwrdmoreno]

https://t.co/wgiv0TFZXA

[J. Edward Moreno @edwrdmoreno]

Psychedelic biotechs inch toward commercialization, now with Trump’s blessing $PSIL $CMPS $DFTX $GHRS $PBM

[Luke Kawa @LJKawa]

S&P 500 12M forward earnings estimates <up> 8%
S&P 500 <down> 8%

War and AI doubts have fueled an unprecedented divergence between stock prices and earnings estimates

https://t.co/op1buWsF30

[J. Edward Moreno @edwrdmoreno]

https://t.co/OKzuZLkOq7

[J. Edward Moreno @edwrdmoreno]

With certain peptides potentially getting off the FDA's no-compounding list, companies are rushing to establish legitimate supply chains. Meanwhile, search interest in the US for “peptides” has skyrocketed and now even surpassed “Ozempic.”

[J. Edward Moreno @edwrdmoreno]

New from me: Strive, the compounding pharmacy behind $Hims short-lived Wegovy pill copy, was already under state scrutiny. https://t.co/Q2IYFjxqnc

[J. Edward Moreno @edwrdmoreno]

$NVO said it has sued $HIMS for patent infringement. https://t.co/keDl7SiSSx

[J. Edward Moreno @edwrdmoreno]

https://t.co/YrWTU2dw8x

[J. Edward Moreno @edwrdmoreno]

The FDA just said it would take "decisive steps" against GLP-1 compounders, name-dropping $hims.

[J. Edward Moreno @edwrdmoreno]

$Hims, long flying under regulators’ radar, finally struck a nerve with its copy of $Nvo's Wegovy pill.
https://t.co/kFa4Li9N7k

[J. Edward Moreno @edwrdmoreno]

$Hims, long flying under regulators’ radar, finally struck a nerve with its copy of $Nvo's Wegovy pill.
https://t.co/kFa4Li9N7k

[J. Edward Moreno @edwrdmoreno]

https://t.co/KLF3PiXxva

[J. Edward Moreno @edwrdmoreno]

$HIMS said it would sell copies of $NVO's Wegovy pill at a lower price. The drugmaker, which has sued other companies making dupes but not Hims, said it "will take legal and regulatory action."

[Luke Kawa @LJKawa]

WEIGHT LOST INTEREST

Ozempic’s soft power has been eclipsed by Zepbound
(via @edwrdmoreno) https://t.co/HU49Y0qSpk

[J. Edward Moreno @edwrdmoreno]

https://t.co/LDYNHwYBRw

[J. Edward Moreno @edwrdmoreno]

$NVO's Ozempic is no longer the most-searched for GLP-1 in the US, with $LLY's Zepbound taking its place